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EDITORIAL
Mammalian malaria: Remembering the Alamo 
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Much attention has been directed toward a recent slowing 
of progress in malaria control worldwide, with particular 
emphasis on growing evidence which suggests that the 
twin pillars of malaria reduction – chemotherapy and 
anti-mosquito measures – are both less effective than 
previously. This special issue of Virulence gathers papers 
with a different perspective – understanding the response 
of the mammalian host to infection with the Plasmodium 
parasite. Taken together, this collection of writing is based 
on an implicit understanding of the human body as 
a fortress against invasion by the marauding parasite. 
Innate defenses such as fever, phagocytosis, and systemic 
inflammation, and the pathogen-elicited adaptive 
responses of cellular immunity and antibody are the 
walls, ramparts, boiling oil, and fortified gates that protect 
us from malaria, as from other infections. In this series, 
our panel of expert authors examine how these defenses 
work, the parasite’s strategies for eluding them, what 
happens when they fail and progression to severe disease 
occurs, and how biomarkers of the body’s defense systems 
can be valuable diagnostic indicators of morbidity and 
prognosis. This knowledge is of great value in the con-
tinued effort to develop improvements in the manage-
ment of severe malaria, by directing defenses down 
beneficial pathways to minimize pathology, and in the 
design of effective vaccines against Plasmodium parasites.
Decision making in the host microvasculature
The endothelium of the microvasculature of the human 
host is a crucial tissue in P. falciparum infection. 
Parasite-derived ligands on the surface of the infected 
erythrocyte mediate receptor binding, enabling seques-
tration of maturing blood-stage asexual parasites away 
from splenic filtration. This binding results in endothe-
lial activation and damage to the vessels, and this injury 
is a key feature of severe life-threatening malaria (SM). 
This is an example of harmful host responses which can 
lead to increased pathology. However, only a minority 
of infections progress to SM, and so the host is usually 
able to manage this interaction. Clara Erice and Kevin 
Kain [1] explore the processes that lead to these very 
different outcomes and consider ways to exploit any 
host molecules indicative of very early endothelial 
responses as biomarkers for risk of progression to SM. 
Patel, Dunican, and Cunnington [2] also train 
a microscope on features of disease progression, but 
concentrate on pediatric SM at admission – what fea-
tures of the illness can be utilized as biomarkers to 
assist in reaching a rapid prognosis and permit optimal 
management of each child on a case-by-case basis? 
These considerations could lead to an understanding 
of how to intervene in such a way as to guide immune 
responses in malaria patients toward reduced pathology 
and so better outcomes.
Inflammatory immunopathology and the 
marshaling of antibody defenses
Inflammation is a feature of illness caused by all 
Plasmodium species, and has been examined closely in 
experimental rodent infections, where its potential to 
contribute to immunopathology and SM is well known. 
Lisa Drewry and John Harty [3] guide us through 
a substantial literature elucidating the symphonic action 
of innate, cellular, and antibody responses of the immune 
system to parasite infection, the result being a crescendo 
of inflammation and potential risk of pathology if IFN-γ 
and Th1 T-cells are conducting the orchestra. In contrast, 
TGF-β and IL-10 can guide the immune players to an 
anti-inflammatory state, with a lower risk of pathology. 
The authors look closely at the role of regulatory T-cells in 
these events. Hahn, Pepper and Liles [4] rather point us to 
the role of B-cells, presenting new data on the signaling 
role of the type III interferon IFNλ, highlighting its sup-
pression of the acute antibody response and thus impe-
dence of parasite clearance early in infection. Allison 
Bucşan and Kim Williamson [5] develop the B-cell 
theme further, asking difficult questions concerning the 
obstacles to the development of effective malaria vaccines 
that elicit a robust humoral attack on the many parasite 
protein antigens involved in erythrocyte invasion. Their 
thesis is that vaccine design should incorporate our 
rapidly developing understanding of the action of parasite 
nucleic acids, haemozoin, and phospholipid, continually 
released by cycles of schizogony, in initiating signaling 
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pathways to elicit antibody responses. Such signaling early 
in infection may be crucial in determining outcomes and 
provide the prognostic markers sought by Patel, Dunican, 
and Cunnington [2].
Oranges are not the only fruit
SM can be the result of infection with Plasmodium species 
other than P. falciparum. Anupkumar Anvikar, Sam 
Wassmer, and colleagues [6] present recent findings 
from severe malaria cases in India caused by infection 
with P. vivax, the most common causative agent for 
malaria on the sub-continent. In the study region, 
Gujarat, severe malaria hospital admissions from vivax 
malaria outnumber those with P. falciparum infections. 
Distinct features of SM in P. vivax disease are discussed, 
such as jaundice, and the observed frequency of severe 
disease in adults, perhaps indicating a waning of malaria 
immunity in this population. This paper is an example of 
“real world” immunology in settings where infections can 
be complex mixes of multiple parasite species simulta-
neously, or where a single individual can experience alter-
nating bouts of malaria caused by different species.
Controlling malaria requires diverse 
approaches
This collection of papers reminds us that, along with the 
need to target mosquito transmission and the necessity of 
providing rapid access to effective malaria drugs, malaria 
control strategies must also enlist the defensive capabilities 
of the human immune system – do not forget the Alamo. 
This is not an easy task, as illustrated by our dearth of 
effective vaccines (only one has been registered for use in 
humans to date, Mosquirix™), our lack of diagnostic mar-
kers for risk of complicated disease and our currently 
imperfect understanding of how to minimize harmful 
pathology in severe malaria. The work described herein is 
therefore presented as an indication of progress using 
a number of promising approaches, each of them a reason 
for optimism that this task may yet be accomplished.
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